Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Key facts

Sponsor

Epygenix

Principal Investigator

Hahn-Jun Lee, Ph.D.

Epygenix Therapeutics, Inc.

Intervention

EPX-100 (Clemizole Hydrochloride)(drug)

Enrollment

24 enrolled

Eligibility

18-50 years · All sexes

Timeline

2019 – 2019

Study locations (1)

• TKL Research, Fair Lawn, New Jersey, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dravet syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07251673
  Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE3NCT06872125
  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  Stoke Therapeutics, Inc
• RECRUITINGPHASE4NCT06598449
  Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
  University of Colorado, Denver
• RECRUITINGPHASE3NCT06660394
  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  Longboard Pharmaceuticals
• ACTIVE NOT RECRUITINGPHASE3NCT06118255
  A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
  UCB BIOSCIENCES, Inc.
• RECRUITINGPHASE1, PHASE2NCT05419492
  A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
  Encoded Therapeutics
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06283212
  A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
  Encoded Therapeutics
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06112275
  A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
  Encoded Therapeutics

See all trials for Dravet syndrome →